Noopept - 10mg - 50pcs - Research Use Only

Pregnancy, breastfeeding period. Age up to 18 years. Hypersensitivity to the components of the drug. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption. Severe disorders of liver and kidney function.

10 mg

Impairments of memory, attention, other cognitive functions and emotionally labile disorders (including in elderly patients) in:
• consequences of traumatic brain injury;
• post-commotion syndrome;
• cerebral vascular insufficiency (encephalopathies of various genesis);
• asthenic disorders;
• other conditions with signs of reduced intellectual productivity.

No interaction of Noopept® with alcohol, sleeping pills and hypotensives and psychostimulating drugs has been established.

No specific manifestations of overdose have been established.

Pharmacological group:
Nootropic agent.

Pharmacokinetics:
Omberacetam, absorbed in the gastrointestinal tract, enters the systemic bloodstream unchanged, penetrates the blood-brain barrier, is determined in the brain in higher concentrations than in the blood. The maximum concentration time is reached on average 15 minutes. The half-life from blood plasma is 0.38 hours. Partially preserved unchanged, partially metabolized to form phenylacetic acid, phenylacetylproline and cycloprolylglycine. It has a high relative bioavailability (99.7%), does not cumulate in the body, does not cause drug dependence.

The drug is contraindicated for use during pregnancy.

If it is necessary to use the drug during breastfeeding, it is necessary to resolve the issue of stopping breastfeeding.

Without a prescription.

Allergic reactions are possible. In patients with arterial hypertension, mostly severe, an increase in blood pressure may be observed while taking the drug.

Store in a dry place, protected from light, at a temperature not higher than 25 C. Store in places inaccessible to children.